about
Once-yearly zoledronic acid in hip fracture preventionToward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ RegimenExpert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case reportDevelopment of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisIntravenous bisphosphonates for postmenopausal osteoporosis.Role of zoledronic acid in the prevention and treatment of osteoporosis.Osteoporotic profiles in elderly patients with symptomatic lumbar spinal canal stenosis.Radiopharmaceuticals for the palliation of painful bone metastases.The role of the bone microenvironment in skeletal metastasis.Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.Skeletal metastasis: treatments, mouse models, and the Wnt signaling.Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions.Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis.Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study.A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.Characterizing the composition of bone formed during fracture healing using scanning electron microscopy techniques.Effect of zoledronate, a third-generation bisphosphonate, on proliferation and apoptosis of human dental pulp stem cells.Imidazoles as potential anticancer agents
P2860
Q24657667-2D7C4EE9-47FD-49D5-B0BF-99FAADB3F76BQ26749972-3A03B2E2-D0B6-4171-B007-C2E8A3AA3657Q27028138-BBD66DBE-33EC-4AE7-AB9E-D18C97CC6902Q28275303-C0001ED9-A9F1-4FA7-A3D1-137BE52DF654Q34042003-6760DF17-84E6-4818-8DE1-BD9D3B8B9CD4Q34863964-F95728F2-F67E-4B43-9C3B-8715C7B446B4Q34984177-9DE5A61D-1AFD-4379-931A-5C6322CE3B28Q36038945-53E5B9D9-12A6-48E5-8A60-7333619CAA81Q36057121-B4FF584F-3EEC-46F9-9164-64FD40DEF7E1Q36491430-2BD1D93F-A4C4-4F29-B09A-A4136B34FD23Q37192926-BE8175F7-DB5B-4858-9585-F18BCBE1E4BDQ37354085-409A261E-240F-4BD9-980F-7F037C17C490Q37996117-2235FB9F-5045-4CF0-9EA5-C987BB2B6270Q38144897-68623071-8A89-4B0A-9557-D8A232B04F6EQ39013796-3AB7E1EC-6110-4C0A-B13F-DC5DC6958F5CQ39272429-4FF1C491-6A01-4146-B1E6-231B6ED5B6AAQ40135167-F56152C2-4D89-4A12-A302-A23F664151CFQ41988617-E0E587B4-7CAA-4061-AABB-EBB65809821DQ46282412-CD7CBED0-FC7B-4838-B535-5F84479A9605Q47994742-CFE78766-AC87-4C2D-8F16-8A61CA090B74Q59149996-0FA1E3F6-2CEF-4EBF-9DA3-1FA52B7A6A87
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Zoledronic acid: a new parenteral bisphosphonate.
@ast
Zoledronic acid: a new parenteral bisphosphonate.
@en
type
label
Zoledronic acid: a new parenteral bisphosphonate.
@ast
Zoledronic acid: a new parenteral bisphosphonate.
@en
prefLabel
Zoledronic acid: a new parenteral bisphosphonate.
@ast
Zoledronic acid: a new parenteral bisphosphonate.
@en
P1476
Zoledronic acid: a new parenteral bisphosphonate.
@en
P2093
Edward C Li
Lisa E Davis
P304
P356
10.1016/S0149-2918(03)80327-2
P577
2003-11-01T00:00:00Z